S A Stacker


Affiliation: Ludwig Institute for Cancer Research
Country: Australia


  1. Stacker S, Achen M. From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy. Lymphat Res Biol. 2008;6:165-72 pubmed publisher
    ..History may show that anti-angiogenesis provided the vantage point from which anti-lymphangiogenesis was seen as a viable concept for targeting tumors and other pathological conditions. ..
  2. request reprint
    Stacker S, Hughes R, Achen M. Molecular targeting of lymphatics for therapy. Curr Pharm Des. 2004;10:65-74 pubmed
    ..Modulating these pathways and other molecules with specificity to the lymphatic system could offer alternative treatments for a number of important clinical conditions. ..
  3. request reprint
    Stacker S, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem. 1999;274:32127-36 pubmed
    ..In situ hybridization demonstrated that embryonic lung is a major site of expression of the VEGF-D gene. Processed forms of VEGF-D were detected in embryonic lung indicating that VEGF-D is proteolytically processed in vivo. ..
  4. request reprint
    Stacker S, Vitali A, Caesar C, Domagala T, Groenen L, Nice E, et al. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem. 1999;274:34884-92 pubmed
    ..These data suggest different mechanisms for VEGF-mediated mitogenesis and vascular permeability and raise the possibility of an alternative receptor mediating vascular permeability. ..